Semaglutide's effectiveness and safety for weight loss and excessive hunger in adults with Prader-Willi syndrome

Prader-Willi syndrome is associated with hyperphagia and early-onset obesity due to hypothalamic dysfunction.

• It is a genetic neurodevelopmental disorder that includes issues such as learning disability and endocrinopathies.
• Management of the syndrome requires strict control of the food environment to mitigate obesity risks.
• Newer medications, specifically glucagon-like peptide-1 receptor agonists like semaglutide, have shown effectiveness in treating obesity outside of PWS.
• There are few case reports regarding the use of these medications in individuals with Prader-Willi syndrome.

Simplified